New combo therapy aims to suppress hepatitis b virus in stubborn cases
NCT ID NCT07090759
First seen Jan 23, 2026 · Last updated Apr 29, 2026 · Updated 11 times
Summary
This study tests a new drug called GST-HG141 (Neracorvir) in people with chronic hepatitis B who still have the virus despite taking standard antiviral pills. About 526 adults aged 18-70 will receive either the new drug or a placebo added to their current medication. The goal is to see if the combination can lower the virus to undetectable levels and improve control of the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shulan(Hangzhou) Hospital
RECRUITINGHangzhou, Zhejiang, 310011, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.